(Q37829771)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21244617%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

review article

1 reference

title

PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21244617%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21244617%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

A Mukhopadhyay

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21244617%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

R Plummer

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21244617%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

R J Edmondson

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21244617%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

18 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21244617%20AND%20SRC:MED&resulttype=core&format=json

BJOG: an International Journal of Obstetrics and Gynaecology

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21244617%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21244617%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21244617%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

429-432

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21244617%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

New targets for cancer chemotherapy--poly(ADP-ribosylation) processing and polyisoprene metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

PARP inhibitors: will the new class of drugs match the hype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

Inhibition of ADP ribosylation prevents and cures helicobacter-induced gastric preneoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X

Efficient Deletion of NormalBrca2-Deficient Intestinal Epithelium by Poly(ADP-Ribose) Polymerase Inhibition Models Potential Prophylactic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2010.02838.X